Continuing Education

DIA 2026 unites global thought leaders, innovators, regulators, government health agencies, academics, patient advocates, and philanthropic organizations across every discipline in the life sciences industry. This premier gathering empowers attendees to continue to advance the discovery, development, and lifecycle management of healthcare products by connecting, collaborating, sharing their knowledge and experience to drive transformative solutions. Designed to deepen and strengthen professionals' understanding of cross-cutting concepts in biopharmaceutical development, DIA 2026 fosters interdisciplinary collaboration that leads to stronger innovation and improved patient health outcomes.

Learning Objectives

At the conclusion of the DIA 2026 Global Annual Meeting, participants should be able to:

• Evaluate emerging global regulatory policies, scientific frameworks, and collaborative models that shape regulatory strategy, policy development, and pathways for global alignment
• Assess advances in clinical trial operations and innovation, including approaches that enhance trial design, execution, efficiency, and participant experience
• Identify best practices for managing safety, pharmacovigilance, and risk across the product lifecycle, and describe tools and methods that support proactive safety monitoring and decision making
• Describe advances in data science, artificial intelligence, digital technologies, and computational tools that strengthen analytics, decision support, and evidence generation
• Apply principles of robust statistical methodology, real world evidence, and quantitative approaches to improve study design, analytical rigor, and interpretation of clinical and safety data
• Examine modern medical affairs and scientific communication practices that enhance scientific exchange, support healthcare decision making, and incorporate insights from clinicians, patients, and other stakeholders
• Describe innovations in CMC, product quality, and manufacturing, and explain how evolving technologies and regulatory expectations influence development, scale-up, and lifecycle management
• Identify approaches to strengthen personalized medicine, diagnostics, and combination product development through improved evidence generation, regulatory clarity, and cross stakeholder integration
• Evaluate strategies that enhance professional development, leadership, and project, program, and portfolio management capabilities within the life sciences ecosystem

Specific learning objectives for each educational offering can be found on the DIA 2026 website under the program schedule.

Select short courses and program offerings (including sessions, forums, and workshops) may be approved for AMA PRA Category 1 Credits™, pharmacy, or nursing contact hours, Project Management Institute (PMI) professional development units (PDUs), or International Accreditors for Continuing Education and Training (IACET) continuing education units (CEUs). Continuing education credit information will be clearly identified on the DIA 2026 website with the statement CME, Pharmacy, Nursing, or PMI PDUs. CE credits are not available for the Plenary Sessions, Keynote Address, Innovation Theater presentations, Content Hubs, Community Rounds, Posters, LIFT Sessions, and Sponsored events.

Accreditation

• Joint Accreditation Statement

  

  In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DIA. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

  Physician Continuing Medical Education

  The Postgraduate Institute for Medicine designates this live activity for a maximum of 20.25 (8.25 for the Short Courses and 12 for the Annual Meeting Sessions) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  Continuing Nursing Education

  The maximum number of hours awarded for this Continuing Nursing Education activity is 20.25 contact hours (8.25 for the Short Courses and 12 for the Annual Meeting Sessions). California Board of Registered Nursing, Provider Number 13485, approved for 20.25 contact hours.

• Accreditation Council for Continuing Medical Education (ACCME)

  

  This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine (PIM) and the Drug Information Association (DIA). PIM is accredited by the ACCME to provide continuing medical education for physicians.

• Accreditation Council for Pharmacy Education (ACPE)

  

  DIA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation. This program is designated for up to 37.75 contact hours or 3.775 continuing education units (CEU's), (25.75 contact hours or 2.575 CEUs for the Short Courses and 12 contact hours or 1.2 CEUs for the Annual Meeting Sessions).

  ACPE Credit Requests MUST BE SUBMITTED by Friday, July 31, 2026. DIA is required by the Accreditation Council for Pharmacy Education (ACPE) to report pharmacy-requested CEUs through the CPE Monitor system. All ACPE-certified activity credit requests need to be submitted through DIA’s My Transcript within 45-days post activity. If ACPE credit is not requested by Friday, July 31, 2026, the CEU request will not be transmitted through to the CPE Monitor. Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit nabp.pharmacy.

• American Nurses Credentialing Center (ANCC)

  PIM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

  
  

  DIA has been reviewed and approved as a provider of project management training by the Project Management Institute (PMI). Participants may receive up to 8.75 professional development units (PDUs) for attending the Annual Meeting program offerings. All approved DIA designated PMI numbers for approved offerings are found on the DIA 2026 Global Annual Meeting website on each designated offering description.

  The PMI Registered Education Provider logo is a registered mark of the Project Management Institute, Inc.

• International Accreditors for Continuing Education and Training (IACET)

  

  Drug Information Association (DIA) is accredited by the International Accreditors for Continuing Education and Training (IACET) and offers IACET CEUs for its learning events that comply with the ANSI/IACET Continuing Education and Training Standard. IACET is recognized internationally as a standard development organization and accrediting body that promotes quality of continuing education and training.

  As an IACET Accredited Provider, DIA offers CEUs for its programs that qualify under the ANSI/IACET Standard. DIA is authorized by IACET to offer up to 2.1 CEUs (.3 CEUs for each live virtual short course) for this program.

  IACET credit is available only for live, virtual half-day Short Courses.

• Continuing Legal Education

  For attorneys who would like to receive continuing legal education credits for attending DIA 2026, please complete your state's application for credit and submit accordingly. If you require additional information, please contact CE@DIAglobal.org.

• CE Credit Allocation

  Pre-Conference Short Courses – June 9 through June 14, 2026
  Review each Short Course list to see which offerings include CE designation.

  Half-day short courses:

  (9:30 AM – 12:30 PM) Up to 2.75 AMA PRA Category 1 Credits™, or 2.75 pharmacy contact hours or .275 CEUs, or 2.75 nursing contact hours, or .3 IACET CEUs

  (1:00 PM – 4:00 PM) Up to 2.75 AMA PRA Category 1 Credits™, or 2.75 pharmacy contact hours or .275 CEUs, or 2.75 nursing contact hours, 2.75 PMI PDUs, or .3 IACET CEUs

  Full-day short courses:

  (9:00 AM – 5:00 PM) Up to 6.5 pharmacy contact hours or .65 CEUs

  Annual Meeting Program Offerings – June 15–18, 2026

  Up to 12 AMA PRA Category 1 Credits™, or 12 pharmacy contact hours or .12 CEUs, or 12 nursing contact hours, or 8.75 PMI PDUs

• Statements of Credit

  Participants seeking continuing education credit for DIA 2026 must scan their DIA name badge at each offering to record attendance. Badges must be scanned within 15 minutes of the start time. Participants who do not scan their badges within this window of time will not be eligible to request continuing education credit for that session. If a participant attends multiple offerings occurring at the same time, only the last scanned entry will be recorded.

  To receive a statement of credit for the sessions you attend at the conference, you must request CE credit online through My Transcript beginning Thursday, June 25, 2026 (see instructions below). A statement of credit will be available for download once your credit request has been successfully submitted. Please note that additional requirements apply to physicians.

  To access My Transcript:

  • Visit DIAglobal.org and Sign In with your DIA User ID and Password
  • Select the Welcome Menu in the upper right-hand corner
  • Select My Account, then My Transcript, then Manage My Transcripts (available June 25, 2026)
  • ACPE credit requests must be submitted by Friday, July 31, 2026

  For Physicians only:

  After completing the evaluation for each session, AMA PRA Category 1 Credits™ may be requested through Postgraduate Institute for Medicine:

  • Visit www.cmeuniversity.com and log in or create an account
  • Enter 19314 in "Find Post-Test/Evaluation by Course"
  • Select the activity from the menu and select the desired credit type
  • Download or print your certificate

• Disclaimer

  Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the DIA. Speakers, agenda, and CE information are subject to change without notice.

  Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.

• Disclosure of Conflicts of Interest

  The Postgraduate Institute for Medicine (PIM) and DIA require faculty, planners, managers and other individuals who are in a position to control the content of this activity to disclose all their financial relationships with ineligible companies they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted and mitigated by PIM and DIA according to PIM policy for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Disclosure statements will be included on a slide in each meeting room, as well as on the DIA 2026 website.

• Americans with Disabilities Act (ADA)

  Reasonable accommodations will be made available to persons with disabilities who attend an educational activity. Contact the DIA office in writing at least 15 days prior to event to indicate your needs.